172 related articles for article (PubMed ID: 38496158)
21. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells.
Kamijo K; Murayama H; Uzu T; Togashi K; Kahaly GJ
Thyroid; 2010 Aug; 20(8):851-6. PubMed ID: 20615137
[TBL] [Abstract][Full Text] [Related]
22. Graves' disease following subacute thyroiditis.
Nakano Y; Kurihara H; Sasaki J
Tohoku J Exp Med; 2011 Dec; 225(4):301-9. PubMed ID: 22112923
[TBL] [Abstract][Full Text] [Related]
23. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
24. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease.
Bohbot NL; Young J; Orgiazzi J; Buffet C; François M; Bernard-Chabert B; Lukas-Croisier C; Delemer B
Eur J Endocrinol; 2006 Mar; 154(3):367-72. PubMed ID: 16498048
[TBL] [Abstract][Full Text] [Related]
25. Incomplete thyrotroph suppression determined by third generation thyrotropin assay in subacute thyroiditis compared to silent thyroiditis or hyperthyroid Graves' disease.
Ito M; Takamatsu J; Yoshida S; Murakami Y; Sakane S; Kuma K; Ohsawa N
J Clin Endocrinol Metab; 1997 Feb; 82(2):616-9. PubMed ID: 9024264
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
[TBL] [Abstract][Full Text] [Related]
27. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
28. Eosinophil/Monocyte Ratio Combined With Serum Thyroid Hormone for Distinguishing Graves' Disease and Subacute Thyroiditis.
Hu Y; Zhou D; Chen J; Shan P
Front Endocrinol (Lausanne); 2020; 11():264. PubMed ID: 32457697
[No Abstract] [Full Text] [Related]
29. Comparison of
Jin M; Ahn J; Jo SG; Park J; Jeon MJ; Kim WG; Kim TY; Kim WB; Shong YK; Ryu JS
Nucl Med Mol Imaging; 2022 Feb; 56(1):42-51. PubMed ID: 35186158
[TBL] [Abstract][Full Text] [Related]
30. Use of color Doppler ultrasonography to measure thyroid blood flow and differentiate graves' disease from painless thyroiditis.
Hiraiwa T; Tsujimoto N; Tanimoto K; Terasaki J; Amino N; Hanafusa T
Eur Thyroid J; 2013 Jun; 2(2):120-6. PubMed ID: 24783050
[TBL] [Abstract][Full Text] [Related]
31. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.
Macchia E; Concetti R; Borgoni F; Cetani F; Fenzi GF; Pinchera A
Autoimmunity; 1989; 3(2):103-12. PubMed ID: 2577491
[TBL] [Abstract][Full Text] [Related]
32. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
[TBL] [Abstract][Full Text] [Related]
33. HLA typing of patients who developed subacute thyroiditis and Graves' disease after SARS-CoV-2 vaccination: a case report.
Yasuda S; Suzuki S; Yanagisawa S; Morita H; Haisa A; Satomura A; Nakajima R; Oikawa Y; Inoue I; Shimada A
BMC Endocr Disord; 2023 Mar; 23(1):54. PubMed ID: 36879263
[TBL] [Abstract][Full Text] [Related]
34. Comparison of serum thyrotrophin concentrations determined by a third generation assay in patients with various types of overt and subclinical thyrotoxicosis.
Kasagi K; Kousaka T; Misaki T; Iwata M; Alam MS; Konishi J
Clin Endocrinol (Oxf); 1999 Feb; 50(2):185-9. PubMed ID: 10396360
[TBL] [Abstract][Full Text] [Related]
35. Hyperthyroidism.
Chaker L; Cooper DS; Walsh JP; Peeters RP
Lancet; 2024 Feb; 403(10428):768-780. PubMed ID: 38278171
[TBL] [Abstract][Full Text] [Related]
36. Increased pertechnetate and radioiodine uptake in the thyroid gland with subacute thyroiditis and concurrent Graves' disease.
Li L; Sun L; Yu S; Ma C
Hell J Nucl Med; 2016; 19(1):49-52. PubMed ID: 26929941
[TBL] [Abstract][Full Text] [Related]
37. Cut off value of technetium uptake in the differential diagnosis of Graves
Fadime D
Asia Ocean J Nucl Med Biol; 2020; 8(1):54-57. PubMed ID: 32064283
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous occurrence of subacute thyroiditis and Graves' disease.
Hoang TD; Mai VQ; Clyde PW; Shakir MK
Thyroid; 2011 Dec; 21(12):1397-400. PubMed ID: 22136271
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease.
Zhou Y; Zhou M; Qi Y; Wang W; Chen X; Wang S
Ther Adv Endocrinol Metab; 2021; 12():20420188211044943. PubMed ID: 34603682
[TBL] [Abstract][Full Text] [Related]
40. Duplex Hemodynamic Parameters of Both Superior and Inferior Thyroid Arteries in Evaluation of Thyroid Hyperfunction Disorders.
Assem Hussein M; Abdel Hamid A; M Abdel Samie R; Hussein E; Sadik Elsawy S
Int J Gen Med; 2022; 15():7131-7144. PubMed ID: 36110917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
